← All reportsView on Symbol
AKTS

AKTS

Watchlist

Aktis Oncology, Inc.

Healthcare · NASDAQ

$1.2B mkt cap

Brief updated Jun 15, 2026

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical t

Decifer Research·Data summary

AKTS is a watchlist-conviction name in Healthcare

AKTS sits at the intersection of key themes currently active in the market. The scoring engine rates it watchlist based on how well the active market forces line up with its business, plus available fundamental data. Financial metrics and analyst consensus provide additional context.

Why now

The market forces active right now are aligned with the company's core business exposure. The timing reflects the intersection of theme strength and available catalyst data.

Key risks

Data availability limits full scoring across all dimensions. Market forces can reverse rapidly; theme exposure does not guarantee the price follows. Fundamental valuation data may not reflect the most recent quarterly results.

What to watch

Monitor conviction score changes, especially the macro and analyst dimensions. Earnings guidance updates and analyst consensus shifts are the primary near-term catalysts.

48Watchlist Conviction
macro
0/25
analyst
22/38
momentum
20/20
forward catalyst
0/15
valuation
15/23
highs
-5/12
news catalyst
0/12
options flow
0/12
peer network
0/8
counter thesis
0/3
Key financials
Revenue growth (YoY)7257.0%
Gross margin8919.0%
Operating margin-92398.0%
Net margin-75488.0%
P/E ratio-26.6x
Return on equity-13027.0%
FCF yield-517.0%
Debt / equity0.0x
EV / sales134.5x
Valuation
Analyst consensusBUY
DCF fair value$2
Next EPS estimate$-0.93
Macro context

Stock Market Today: Dow Drops 400 Points, Small Caps Crater On U.S.-Iran Unease; Macy's Wobbles (Live Coverage)

The Dow Jones dropped 400 points and small caps declined significantly due to rising tensions between the U.S. and Iran, sparking geopolitical uncertainty and risk-off sentiment in the markets. This escalation has the potential to impact global markets and asset classes.

Jun 3, 2026

SLB N.V. (SLB): A Top Oil Stock to Buy amid US-Iran War on Expected Growth

The US-Iran conflict is escalating, which could lead to increased geopolitical risk and potentially disrupt oil supplies, making SLB N.V. a potentially attractive investment due to expected growth.

Jun 3, 2026

Update: WTI Oil Rises Again as the United States and Iran Trade Strikes

The United States and Iran have engaged in trade strikes, leading to a rise in WTI oil prices as geopolitical tensions escalate in the region. This conflict has the potential to disrupt global oil supplies and impact markets.

Jun 3, 2026

Oil Rises Again as the United States and Iran Trade Strikes

The United States and Iran have engaged in a series of military strikes, leading to increased tensions in the Middle East and a subsequent rise in oil prices. This conflict has the potential to disrupt global oil supplies and impact the broader macro environment.

Jun 3, 2026

Analyst intelligence
4 Buy3 Hold0 Sell
Earnings intelligence

Earnings surprises

-22.6%

2026-05

+15.8%

2026-03

Generated Mon, 15 Jun 2026 05:23:56 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.